Genomma Lab Internacional, S.A.B. de C.V.
Mexican Stock ExchangeTotal Valuation
Genomma Lab Internacional, S.A.B. de C.V. carries a market capitalization of 14.99B, placing it among publicly traded companies globally. Its enterprise value stands at 22.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 14.99B |
| Enterprise Value | 22.99B |
Share Statistics
Genomma Lab Internacional, S.A.B. de C.V. currently has 977.75M shares outstanding.
| Shares Outstanding | 977.75M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Genomma Lab Internacional, S.A.B. de C.V. trades at a trailing price-to-earnings ratio of 15.17. The price-to-sales ratio is 1.38, and the price-to-book ratio stands at 1.23.
| PE Ratio | 15.17 |
| PS Ratio | 1.38 |
| PB Ratio | 1.23 |
| P/TBV Ratio | 2.91 |
| P/FCF Ratio | 10.21 |
| P/OCF Ratio | 11.55 |
Enterprise Valuation
On an enterprise value basis, Genomma Lab Internacional, S.A.B. de C.V. trades at an EV/EBITDA multiple of 8.39 and an EV/FCF ratio of 10.89. The EV/Sales ratio of 1.78 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.39 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.78 |
| EV / EBITDA | 8.39 |
| EV / EBIT | 8.39 |
| EV / FCF | 10.89 |
Financial Position
Genomma Lab Internacional, S.A.B. de C.V. maintains a current ratio of 1.79, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.78, indicating elevated leverage, while an interest coverage ratio of 4.87 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.79 |
| Quick Ratio | 0.37 |
| Debt / Equity | 68.78 |
| Debt / EBITDA | 2.94 |
| Interest Coverage | 4.87 |
Financial Efficiency
Genomma Lab Internacional, S.A.B. de C.V. posts a return on equity of 8.33 and a return on invested capital of 9.46.
| Return on Equity (ROE) | 8.33 |
| Return on Assets (ROA) | 4.78 |
| Return on Invested Capital (ROIC) | 9.46 |
| Return on Capital Employed (ROCE) | 7.15 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.31 |
Taxes
Over the trailing twelve months, Genomma Lab Internacional, S.A.B. de C.V. has paid 599.75M in income taxes, reflecting an effective tax rate of 33.90.
| Income Tax | 599.75M |
| Effective Tax Rate | 33.90 |
Stock Price Statistics
Genomma Lab Internacional, S.A.B. de C.V.'s stock has declined approximately -24.51994% over the past 52 weeks. The 50-day moving average sits at 15.59, while the 200-day moving average is 17.36.
| Beta (5Y) | N/A |
| 52-Week Price Change | -24.51994% |
| 50-Day Moving Average | 15.59 |
| 200-Day Moving Average | 17.36 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Genomma Lab Internacional, S.A.B. de C.V. generated 12.88B in revenue and converted that into 1.17B in net income, yielding earnings per share of 1.20. EBITDA reached 2.74B, while operating income came in at 2.74B.
| Revenue | 12.88B |
| Gross Profit | 8.08B |
| Operating Income | 2.74B |
| Pretax Income | 1.77B |
| Net Income | 1.17B |
| EBITDA | 2.74B |
| EBIT | 2.74B |
| Earnings Per Share (EPS) | 1.20 |
Balance Sheet
Genomma Lab Internacional, S.A.B. de C.V. holds 2.81B in cash and equivalents against 8.06B in total debt, resulting in a net debt position of 1.92B. Total book value stands at 14.44B, with working capital of 6.01B providing operational flexibility.
| Cash & Cash Equivalents | 2.81B |
| Total Debt | 8.06B |
| Net Debt | 1.92B |
| Equity (Book Value) | 14.44B |
| Book Value Per Share | 14.78 |
| Working Capital | 6.01B |
Cash Flow
Genomma Lab Internacional, S.A.B. de C.V. produced 1.54B in operating cash flow over the past twelve months. After subtracting -201.84M in capital expenditures, free cash flow totaled 1.33B - equivalent to 1.37 per share.
| Operating Cash Flow | 1.54B |
| Capital Expenditures | -201.84M |
| Free Cash Flow | 1.33B |
| FCF Per Share | 1.37 |
Margins
Genomma Lab Internacional, S.A.B. de C.V. operates with a gross margin of 62.68, reflecting its pricing power and cost economics. The operating margin of 21.26 and net profit margin of 9.08 provide insight into operational efficiency.
| Gross Margin | 62.68 |
| Operating Margin | 21.26 |
| Pretax Margin | 13.73 |
| Profit Margin | 9.08 |
| EBITDA Margin | 21.26 |
Dividends & Yields
The company's payout ratio of 33.41 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.40 |
| Dividend Yield | N/A |
| Payout Ratio | 33.41 |
| Shareholder Yield | -0.21 |
| FCF Yield | 9.80 |
Stock Splits
Genomma Lab Internacional, S.A.B. de C.V.'s most recent stock split took place on August 2, 2010 with a 1:2 split ratio.
| Last Split Date | 8/2/2010 |
| Split Ratio | 1:2 |
Scores
Genomma Lab Internacional, S.A.B. de C.V. posts an Altman Z-Score of 3.25, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.25 |